8-(1-Azabicyclo[2.2.2]octan-3-yl)-2-pyridin-3-yl-3,6-dihydropyrrolo[3,2-e]benzimidazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 8-(1-Azabicyclo[2.2.2]octan-3-yl)-2-pyridin-3-yl-3,6-dihydropyrrolo[3,2-e]benzimidazole
• 化学式: C₂₁H₂₁N₅
• 分子量: 343.4
• InChiKey: WLROTSPNQDIYJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  60.6
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Dihydroimidazo[4,5-e]indole and 7h-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor liqands and/or serotonergic ligands
  申请人：——

  公开号：US20040142935A1

  公开（公告）日：2004-07-22

  Compounds of the formula (I) in which R 1 , R 2 , R 3 and R 4 are as defined in Claim 1, are ligands of the nicotinic acetylcholine receptor and/or serotonergic ligands and are suitable for the prophylaxis or treatment of psychoses, schizophrenia, depression, anxiety states, dementia, in particular Alzheimer's disease and Lewy bodies dementia, neurodegenerative disorders, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, Tourette's syndrome, learning and memory restrictions, bulimia, anorexia nervosa or other eating disorders, compulsive behaviour, pre-menstrual syndrome, age-induced memory impairment, amelioration of withdrawal symptoms in nicotine dependence. Strokes or brain damage by toxic compounds, and for the treatment of disorders which are characterised by an excess of circulating serotonin or by serotonergic hyperactivity. 1

  式(I)中，R1、R2、R3和R4如权利要求1所定义的化合物是尼古丁酸乙酰胆碱受体的配体和/或5-羟色胺受体的配体，适用于预防或治疗精神病、精神分裂症、抑郁症、焦虑状态、痴呆症，特别是阿尔茨海默病和李氏小体痴呆、神经退行性疾病、帕金森病、肌萎缩性侧索硬化症、亨廷顿病、抽动症、学习和记忆障碍、贪食症、厌食症或其他进食障碍、强迫行为、经前综合征、年龄引起的记忆障碍、改善尼古丁依赖的戒断症状、中风或毒性化合物引起的脑损伤，并用于治疗其循环中5-羟色胺过多或5-羟色胺活性亢进的疾病。
• DIHYDROIMIDAZO¬4,5-E INDOLE AND 7H-PYRROLO¬3,2-F QUINOXALINE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND/OR SEROTONERGIC LIGANDS
  申请人：Merck Patent GmbH

  公开号：EP1383774B1

  公开（公告）日：2008-05-07
• DIHYDROIMIDAZO[4,5-E]INDOLE AND 7H-PYRROLO[3,2-F]QUINOXALINE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND/OR SEROTONERGIC LIGANDS
  申请人：MERCK PATENT GmbH

  公开号：EP1383774A2

  公开（公告）日：2004-01-28
• US7279496B2
  申请人：——

  公开号：US7279496B2

  公开（公告）日：2007-10-09
• [EN] DIHYDROIMIDAZO[4,5-E]INDOLE AND 7H-PYRROLO[3,2-F]QUINOXALINE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND/OR SEROTONERGIC LIGANDS<br/>[FR] DERIVES DE DIHYDROIMIDAZO[4,5-E]INDOLE ET DE 7H-PYRROLO[3,2-F]QUINOXALINE UTILISES COMME LIGANDS DE RECEPTEUR DE L'ACETYLCHOLINE NICOTINIQUE ET/OU LIGANDS SEROTONINERGIQUES
  申请人：MERCK PATENT GMBH

  公开号：WO2002088143A2

  公开（公告）日：2002-11-07

  Compounds of the formula (I) in which R?1, R2, R3 and R4¿ are as defined in Claim 1, are ligands of the nicotinic acetylcholine receptor and/or serotonergic ligands and are suitable for the prophylaxis or treatment of psychoses, schizophrenia, depression, anxiety states, dementia, in particular Alzheimer's disease and Lewy bodies dementia, neurodegenerative disorders, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, Tourette's syndrome, learning and memory restrictions, bulimia, anorexia nervosa or other eating disorders, compulsive behaviour, premenstrual syndrome, age-induced memory impairment, amelioration of withdrawal symptoms in nicotine dependence. Strokes or brain damage by toxic compounds, and for the treatment of disorders which are characterised by an excess of circulating serotonin or by serotonergic hyperactivity.